FDA Chief Scientist Schwetz May Have Larger Role Under Henney
This article was originally published in The Gray Sheet
Executive Summary
FDA Interim Chief Scientist and National Center for Toxicology Research Director Bernard Schwetz, PhD, may be in line for a more prominent role at FDA under Commissioner Jane Henney.
You may also be interested in...
FDA Senior Advisor For Science Schwetz Named Acting Deputy Commissioner
FDA Senior Advisor for Science Bernard Schwetz, PhD, will serve as acting deputy commissioner as the agency searches for a permanent appointee for the office vacated by Michael Friedman, MD.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.